IGF-1 stimulates growth of new blood vessels in experimental systems (Nakao-Hayashi et al, 1992) and potentially SRIF analogues may inhibit tumour growth indirectly by decreasing IGF-1 production. The gene discussed is IGF1; the disease is neoplasm.